PALABA Trial

Evidence quality

Other

Highlighted claims

• PALABA was a randomized, open-label, multicenter clinical trial at 14 rheumatology centers in Spain. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Seventy-three participants were randomized, with 37 assigned to abatacept and 36 assigned to hydroxychloroquine. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• The primary outcome was persistent arthritis lasting more than one week in the same joint and fulfilling 2010 rheumatoid arthritis classification criteria during 24 months. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• PALABA enrolled adults with early seropositive palindromic rheumatism and compared treatments over 24 months. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• Eligible participants had palindromic rheumatism, disease duration from at least 3 months to less than 3 years, and rheumatoid factor or ACPA positivity. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial
• The open-label design was the main limitation of the trial. — Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial